Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13011761 | 0.91 | CNR2 (0.50) | CNR1CNR2HTR2BPTGER4HTR7 | |
| SCHEMBL13011314 | 0.84 | PTGER4 (0.59) | CNR1CNR2PTGER4HTR7NPY5R | |
| SCHEMBL2482662 | 0.83 | HTR2B (0.49) | ATMHTR2BHTR7 | |
| SCHEMBL13011760 | 0.83 | HTR2B (0.49) | HTR2BHTR7 | |
| SCHEMBL13011755 | 0.82 | HPGD (0.57) | CNR1CNR2HTR2BHTR7 | |
| SCHEMBL13011305 | 0.80 | CNR1 (0.58) | CNR1ATMNPY5R | |
| SCHEMBL13011754 | 0.80 | NPC1 (0.55) | CNR1CNR2 | |
| SCHEMBL13061931 | 0.79 | CNR2 (0.46) | CNR2HTR2BPTGER4HTR7 | |
| SCHEMBL13011633 | 0.78 | CNR2 (0.50) | CNR1CNR2HTR2BPTGER4HTR7 | |
| SCHEMBL3767125 | 0.77 | CYP19A1 (0.53) | CNR1CNR2HTR2BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | CNR1 776/4885ATM 3637/4885CNR2 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.